Genmab — November 2019

[Bulder]

2½ mia milestenen er stensikker. Den ventes af alle, og vil ikke rykke noget. 3 mia milestenen kommer der først nyt om ved nytår, så det rykker heller ikke noget lige med det første.

[Plimsoller]

Der kan jo ligeså godt blive til +10% som det kan blive -10% resten af året.

[Bulder]

Jo, og når vi nu ser hvad der sker ovre i AMBU, kan shortinddækning også komme på tale allerede i år.

[nohope]

Cup with handle - jeg kan godt få øje på håndtaget nu, det sidder desværre ovre på AMBU.

[Sukkeralf]

ResearchGate - Temporarily Unavailable

(www.researchgate.net)

[Sukkeralf]

Måske en kommende kandidat hen ad vejen:

[Sukkeralf]

Lidt ASH kommentarer - spændende med mulig late breaker for GSKs BCMA ADC

[Sukkeralf]

301 Moved Permanently

(www.evaluate.com)

[E_L]

maybe the full article clarifies a bit
http://sci-hub.tw/https://www.tandfonline.com/doi/abs/10.1080/2162402X.2019.1648171?journalCode=koni20 . Or maybe not.

[E_L]

it works for me, in Chrome and Internet Explorer ?

[E_L]

timing wise it would makes sense as BioNtech and Aduro/BioNovion both partnered with Genmab in 2015? if i am not mistaken...

[E_L]

so given recent trials with BioNtech I mean, could be time for Aduro

[E_L]

“The achievement of starting a Phase I/IIa clinical trial with a product candidate developed in only four years is a validation of our highly productive partnership with Genmab,” said Prof. Ugur Sahin, CEO of BioNTech - RE timing

[Sukkeralf]

Aduro and Genmab has terminated their collaboration

[E_L]

o really? i missed that...

[Bulder]

Sukker, hvad mener du om den bispecifikke car-t - bcma x cd38. Jacob Plieth nævner den ikke. Men Usmani er begejstret. https://ash.confex.com/ash/2019/webprogram/Paper130340.html

[Sukkeralf]

This collaboration was
terminated in the fourth quarter of 2018.

[Sukkeralf]

Page 41

[Sukkeralf]

https://ir.genmab.com/static-files/2d42acad-9313-4900-9e0e-12c6cf16f10d

[E_L]

ok , thks, the paper may have started before, it reads "Financial support for this work was obtained
from Aduro Biotech Europe and Genmab." Given that the Genmab authors get "Acknowledgments" it may be Aduro that now runs with it?